Global X Genomics & Biotechnology ETF – NASDAQ:GNOM

Add to watchlist

$9.12

-0.72

-7.32%

Market closed

Open in about 11 hours

-12.69%

month

-12.69%

quarter

-16.41%

year

Market Cap	78.19M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-1.76

Revenue	19.34M
EBITDA	-45.05M
Income	-59.82M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	-232.91%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM): Profit margin
Dec 2011	2.46M	-22.32M	-904.09%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM): Debt to assets
Dec 2011	130203000	47.58M	36.55%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM): Cash Flow
Dec 2011	-17.13M	28.87M	427K

Global X Genomics & Biotechnology ETF
Latest News

Tuesday, 3 December 2024
09:01	Best-Performing ETF Areas of Last Week	zacks.com
Monday, 8 July 2024
09:00	The 3 Best Gene Editing Stocks to Buy in July 2024	investorplace.com
Friday, 10 May 2024
06:00	Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life	investorplace.com
Thursday, 2 May 2024
06:04	3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire	InvestorPlace
Friday, 22 March 2024
15:49	GNOM: Genomics Still Waiting For Its 'ChatGPT' Moment	Seeking Alpha
Thursday, 21 March 2024
16:19	3 Stocks That Could Be the Next Big Thing in Gene Editing	InvestorPlace
Tuesday, 13 February 2024
06:05	3 Gene Editing Stocks With Unprecedented Surge Potential	InvestorPlace
Wednesday, 31 January 2024
12:28	3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential	InvestorPlace
Wednesday, 18 October 2023
11:05	3 Gene Editing Stocks to Generate Super-Charged Gains	InvestorPlace
Monday, 14 August 2023
08:15	Healthcare Dashboard For August And Focus On GNOM	Seeking Alpha
Sunday, 28 May 2023
04:02	GNOM: A Genomics ETF That Will Have Its Day, Even If Not Right Now	Seeking Alpha
Saturday, 25 March 2023
09:17	The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket	InvestorPlace
Wednesday, 15 March 2023
11:31	The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector	InvestorPlace
Tuesday, 24 January 2023
09:02	Will 2023 be the Year of Cathie Wood ETFs?	Zacks Investment Research
Thursday, 19 January 2023
09:00	GNOM: Healthcare Dashboard For January	Seeking Alpha
Wednesday, 18 January 2023
17:16	GNOM: Get Exposure To The Latest Genomics And Biotechnology Companies	Seeking Alpha
15:40	3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years	InvestorPlace
Wednesday, 11 January 2023
18:09	Can Health Care Stocks Outperform Again In 2023?	Seeking Alpha
Saturday, 15 October 2022
19:01	GNOM: ETF Review And Healthcare Dashboard For October	Seeking Alpha
Friday, 23 September 2022
09:06	As Biotech Adjusts to “New Normal,” Get Exposure With This ETF	ETF Trends
Saturday, 27 August 2022
04:45	Why Now Could Be The Time To Consider Neuroscience Investments	Seeking Alpha
Friday, 12 August 2022
12:03	A Comprehensive Guide to Genomic ETFs	Zacks Investment Research
Friday, 8 July 2022
09:20	Pharma & Biotech ETFs at One-Month High: Here's Why	Zacks Investment Research
Tuesday, 28 June 2022
17:43	A Comprehensive Guide to Genomic ETFs	Zacks Investment Research
Thursday, 24 March 2022
15:27	GNOM: Poor Historical Performance, Lack Of Focus, Uncertain Future	Seeking Alpha
Wednesday, 24 November 2021
10:24	Equity Market Cap For Technologically Enabled Innovation Likely To Grow Exponentially	Seeking Alpha
Tuesday, 26 October 2021
04:55	ETF Battles: ARKG Vs IDNA Vs GNOM	ETFcom
Monday, 27 September 2021
14:25	Global X Genomics & Biotechnology ETF: Targeted Fund Provides Strong Growth And Steady Dividend	Seeking Alpha
Tuesday, 7 September 2021
14:03	Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan	Zacks Investment Research
Saturday, 14 August 2021
10:00	How Are Genomics ETFs Responding to Q2 Earnings?	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 14 Jan 2024

Week In Review: China Biopharmas Book $9B In Deals During JP Morgan Conference Week
Seeking Alpha 12 Jan 2024

Horiba: Wonderful Japanese Company At A Very Attractive Price
Seeking Alpha 7 Jan 2024

Week In Review: 2024 Kicks Off With 3 Deals Worth A Total Of $4B
Seeking Alpha 23 Jul 2023

Week In Review: Novartis In $1 Billion Deal For DTx Pharma
Seeking Alpha 24 Aug 2022

CytoDyn: It Only Takes One Hit
Seeking Alpha 24 Aug 2022

Coherus: 2022 Is In Many Ways A Make Or Break Year
Seeking Alpha 23 Aug 2022

Can Intellia One-Up Alnylam In Transthyretin Amyloidosis?
Seeking Alpha 15 Aug 2022

Selecta: ImmTOR Could Change Autoimmune Disorder Treatment Landscape
Seeking Alpha 10 Aug 2022

Sarepta: Advancement In DMD Space With SRP-9001 And Licensed MyoAAV
Seeking Alpha 1 Aug 2022

SIGA Technologies: Unjustified Selloff, Loading The Boat, Best Monkeypox Play

Frequently Asked Questions (FAQ)

What's the price of Global X Genomics & Biotechnology ETF stock today?

One share of Global X Genomics & Biotechnology ETF stock can currently be purchased for approximately $9.12.
When is Global X Genomics & Biotechnology ETF's next earnings date?

Unfortunately, Global X Genomics & Biotechnology ETF's (GNOM) next earnings date is currently unknown.
Does Global X Genomics & Biotechnology ETF pay dividends?

Yes, Global X Genomics & Biotechnology ETF pays dividends and its trailing 12-month yield is 0.06% with 0% payout ratio. The last Global X Genomics & Biotechnology ETF stock dividend of $0.01 was paid on 7 Jan 2022.
How much money does Global X Genomics & Biotechnology ETF make?

Global X Genomics & Biotechnology ETF has a market capitalization of 78.19M.
What is Global X Genomics & Biotechnology ETF's stock symbol?

Global X Genomics & Biotechnology ETF is traded on the NASDAQ under the ticker symbol "GNOM".
What is Global X Genomics & Biotechnology ETF's primary industry?

Company operates in the Financial Services sector and Asset Management - Global industry.
How do i buy shares of Global X Genomics & Biotechnology ETF?

Shares of Global X Genomics & Biotechnology ETF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
When Global X Genomics & Biotechnology ETF went public?

Global X Genomics & Biotechnology ETF is publicly traded company for more then 6 years since IPO on 10 Apr 2019.

Global X Genomics & Biotechnology ETF

Exchange:

NASDAQ

Full time employees:

Industry:

Asset Management - Global

Sector:

Financial Services

The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

CIK: 0001432353
ISIN: US37954Y4347
CUSIP: 37954Y434